Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Vivos Therapeutics, Inc.

Ticker
VVOS
Sector
Industry
Report date
November 17, 2026
Valye AI Score

100

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Vivos Therapeutics’ Q3 financial results showing a loss but revenue exceeding expectations, regained Nasdaq stockholders' equity compliance, strategic capacity expansions, and a significant stock deal for SOD Sciences stake and test rights.

Recent developments:
  • Vivos Therapeutics reported a Q3 loss but revenue exceeded expectations, indicating ongoing operational challenges alongside revenue growth [N1].
  • The company regained compliance with Nasdaq stockholders' equity standards as of October 2026, improving its listing status [N6].
  • Vivos advanced its South Florida Sleep Center through a partnership with South Palm Cardiovascular, expanding treatment capabilities [N7].
  • The company boosted capacity in Nevada with a new facility targeting $10 million in revenue, supporting operational scaling [N8].
  • In October 2026, Vivos struck a $12 million stock deal acquiring a stake and test rights from SOD Sciences, expanding its diagnostic offerings [N6].
Overview

Vivos Therapeutics, Inc. develops and markets proprietary oral appliances and therapeutic treatments for obstructive sleep apnea (OSA) and related breathing and sleep disorders. The company’s core offering, The Vivos Method, combines FDA-cleared oral appliances with specific therapeutic protocols to treat mild to severe OSA and snoring. Historically focused on training independent dentists, Vivos has shifted its business model toward acquiring and managing sleep medical practices and establishing Dental and Medical Service Organizations (DSOs and MSOs) to provide integrated diagnostic and treatment services. This pivot includes the acquisition of The Sleep Center of Nevada (SCN) and deployment of specialized Sleep Optimization teams to deliver care. The company also offers multiple clinical pathways tailored to different patient needs and provider types. Vivos has expanded its product and service offerings to appeal to a broader range of healthcare professionals beyond dentistry. The company faces operational challenges related to scaling capacity, provider recruitment, insurance credentialing, and regulatory compliance. Financially, Vivos reported a net loss and liquidity constraints as of Q3 2026 and is addressing Nasdaq listing compliance issues. Additionally, Vivos acquired a minority stake and co-ownership interest in a pseudohypoxia early-warning test from SOD Sciences, which carries clinical and commercial uncertainties.

Executive summary

Vivos Therapeutics, Inc. is a medical technology and healthcare services company focused on proprietary oral appliances and therapeutic treatments for obstructive sleep apnea (OSA) and related disorders. The company has transitioned its business model from primarily training independent dentists to a medical-provider focused model involving acquisitions and management of sleep centers and service organizations. The flagship Vivos Method combines FDA-cleared oral appliances with therapeutic protocols, typically over 9 to 12 months, aiming to reduce or eliminate OSA symptoms. The company acquired The Sleep Center of Nevada in 2025 to integrate diagnostics and treatment services, deploying specialized teams to meet patient demand. Financially, as of September 30, 2026, Vivos reported a net loss of $1.945 million, limited liquidity with a current ratio of 0.22, and faces Nasdaq listing compliance challenges due to low stock price. In October 2026, Vivos acquired a minority stake and co-ownership of intellectual property in a pseudohypoxia early-warning test from SOD Sciences, with associated risks including unproven clinical validation and potential dilution from convertible preferred stock. Recent news includes Q3 financial results with revenue above expectations, capacity expansions, and strategic partnerships. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for VVOS

Bull case model:

Vivos Therapeutics has developed a differentiated treatment approach for OSA with its Vivos Method, combining proprietary FDA-cleared oral appliances and therapeutic protocols that may reduce or eliminate the need for lifelong interventions. The company’s pivot to a medical-provider focused model through acquisitions and management of sleep centers, such as The Sleep Center of Nevada, allows it to capture higher-margin diagnostic and treatment revenues and expand patient access. Early operational data from integrated centers indicate potential for significant revenue per deployed treatment team. Strategic partnerships and capacity expansions, including new facilities and collaborations, support scaling efforts. The acquisition of intellectual property and test rights from SOD Sciences could complement the company’s offerings if clinical validation and market acceptance are achieved. Recent news reports indicate revenue growth and regained Nasdaq equity compliance, reflecting progress in execution [N1][N6][N7][N8].

Bear case model:

The company’s new medical-provider focused sales and distribution model is unproven and carries risks related to integration, scaling, and revenue generation. Operational constraints such as limited physical space, provider recruitment challenges, and insurance credentialing delays have limited patient capacity at acquired centers. The pseudohypoxia early-warning test acquired from SOD Sciences is unproven, with uncertain clinical validation, regulatory clearance, and market acceptance, posing risks to anticipated revenue streams. Financially, Vivos faces liquidity constraints with a low current ratio and cash balance, and reported net losses. The company’s stock price has fallen below Nasdaq’s minimum bid requirement, risking delisting, and the proposed reverse stock split carries execution and market risks. Potential dilution from convertible preferred stock issued in the SOD transaction could impact existing shareholders. Failure to successfully implement and scale the new business model could materially harm the company’s prospects [S2].

Moat:

Vivos Therapeutics’ competitive advantage lies in its proprietary Vivos Method, which offers a non-invasive, FDA-cleared treatment for OSA that typically requires only 9 to 12 months of therapy, potentially eliminating the need for lifetime interventions like CPAP or implants. The company’s patented oral appliances have been used in tens of thousands of patients worldwide, supported by a comprehensive therapeutic protocol and adjunctive treatments. The integration of diagnostic and treatment services through acquisitions and management of sleep centers provides a vertically integrated model that may enhance patient access and revenue capture. The company’s evolving business model, including MSO/DSO collaborations and strategic alliances, aims to broaden provider participation and patient reach. However, the moat is challenged by the unproven nature of the new medical-provider focused model, operational scaling constraints, and regulatory and market acceptance risks associated with new test technologies.

Risks overview
Risks summary
The most significant risks include the unproven new business model execution, Nasdaq listing compliance challenges, financial liquidity constraints, and uncertainties related to the SOD Sciences transaction and associated dilution.
Risks details:

• Nasdaq Listing Compliance Risk: The company’s common stock has been below Nasdaq’s minimum bid price requirement, risking delisting. A reverse stock split has been proposed but approval and effectiveness are uncertain, and failure to regain compliance could reduce liquidity and capital raising ability [S2].
• Business Model Execution Risk: The pivot to a medical-provider focused sales and distribution model is unproven with limited operating history. Integration challenges, capacity constraints, provider recruitment, and insurance credentialing delays may limit revenue growth [S2].
• Financial and Liquidity Risk: As of September 30, 2026, the company has limited cash and liquidity with a current ratio of 0.22 and reported net losses, which may constrain operations and growth [S2].
• SOD Sciences Transaction Risk: The acquisition of a minority stake and co-ownership of intellectual property in a pseudohypoxia early-warning test carries risks including unproven clinical validation, regulatory clearance, uncertain market acceptance, and potential impairment. The convertible preferred stock issued could cause substantial dilution [S2].
• Market Acceptance and Competitive Risk: The Vivos Method competes with established OSA treatments such as CPAP and neuro-stimulation implants. Market acceptance depends on clinical outcomes, provider adoption, and patient compliance [S1].

FINAL FORECAST FOR VVOS

Final take one line
Vivos Therapeutics operates a proprietary oral appliance and therapeutic treatment platform for OSA with a pivot to medical-provider integrated services, facing execution and liquidity risks amid Nasdaq compliance challenges.
Final take 12 to 24 month view

Business trends: Transition to a medical-provider focused model integrating sleep centers and expanding diagnostic and treatment services, including new test technologies.
Execution milestones: Integration of The Sleep Center of Nevada, deployment of Sleep Optimization teams, capacity expansions, and strategic partnerships.
Key risks: Unproven new business model execution, liquidity constraints, Nasdaq listing compliance risks, and uncertainties related to the SOD Sciences transaction and potential dilution.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

100
LLM visibility overview
LLM Visibility known facts
  • Vivos Therapeutics, Inc. is a revenue stage medical technology and healthcare services company specializing in proprietary oral appliances and therapeutic treatments for maxillofacial and developmental abnormalities related to breathing and sleep disorders such as obstructive sleep apnea (OSA) and snoring in adults [S1].
  • The company’s core treatment approach is The Vivos Method, which combines oral appliances with therapeutic protocols and is FDA cleared for certain uses. It is estimated to be effective in approximately 80% of compliant OSA cases [S1].
  • Vivos has treated approximately 75,000 patients worldwide with its products, including about 60,000 with its patented C.A.R.E. oral appliances [S1].
  • The company has evolved its business model since 2024 to focus on both appliance sales and healthcare services, including acquiring and managing sleep medical practices and establishing Dental and Medical Service Organizations (DSOs and MSOs) branded as Sleep and Airway Medicine Centers (SAMC) [S1].
  • The company offers three clinical pathways for providers: Guided Growth and Development (pediatric focus), Lifeline (mid-range mandibular advancement devices), and C.A.R.E. (flagship program with patented appliances for mild-to-severe OSA) [S1].
  • As of April 2026, the Guided Growth program is no longer offered to unaffiliated independent dentists; Lifeline and C.A.R.E. continue to be offered to independent dentists and those affiliated with Vivos-supported DSOs [S1].
  • The Vivos Method treatment typically lasts 9 to 12 months and may eliminate the need for lifetime intervention, unlike CPAP or neuro-stimulation implants [S1].
  • The company has shifted towards a medical-provider focused sales, marketing, and distribution model involving acquisitions and alliances with sleep specialty medical providers, exemplified by the June 2025 acquisition of The Sleep Center of Nevada (SCN) [S1].
  • SCN integration involves deploying Sleep Optimization (SO) teams consisting of medical and dental professionals and support staff to provide diagnostics and treatment, with initial locations fully booked through April 2026 and capacity constraints limiting patient intake [S1].
  • Each SO team at SCN has potential to generate collections exceeding $500,000 per month with contribution margins above 50%, based on limited operational data [S1].
  • The company is also implementing a revised MSO/DSO management model for collaborations with sleep centers not acquired outright, involving joint ownership and operational control to ensure business model implementation [S1].
  • The company acquired 3,057,879 shares and a 50% co-ownership interest in intellectual property related to a pseudohypoxia early-warning test from SOD Sciences, Inc. in October 2026, issuing Series C Convertible Preferred Stock valued at $12 million [S2].
  • The pseudohypoxia test is unproven and may not achieve clinical validation, regulatory clearance, or market acceptance; revenue from this test is uncertain and depends on future agreements and clinical outcomes [S2].
  • The Series C Convertible Preferred Stock is convertible into up to 80 million common shares at $0.15 per share, which could cause substantial dilution to existing stockholders if converted [S2].
  • As of September 30, 2026, the company had cash and equivalents of $247,000, current assets of $3.51 million, current liabilities of $16.16 million, resulting in a current ratio of 0.22 and a cash ratio of 0.02, indicating liquidity constraints [S2].
  • The company reported a net loss of $1.945 million and basic and diluted EPS of -$0.07 for the quarter ended September 30, 2026 [S2].
  • Nasdaq notified the company in June 2026 that it was not in compliance with the minimum bid price requirement of $1.00 per share, with a compliance period through December 2, 2026; the stock price was below $0.10 for multiple days in November 2026, risking delisting [S2].
  • The company has proposed a reverse stock split to regain compliance with Nasdaq listing requirements, but approval and effectiveness are uncertain [S2].
  • The company’s new medical-provider focused sales and distribution model is unproven and carries risks related to integration, scaling, and revenue generation [S2].
  • Recent news highlights include the company reporting a Q3 loss but revenue exceeding expectations, regaining compliance with Nasdaq stockholders' equity standards, advancing partnerships and capacity expansions, and executing a $12 million stock deal for SOD Sciences stake and test rights [N1][N6][N7][N8].
Sources
Sources - Context summary

Generated 2026-11-17

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-04-15 | 10-K
  • S2 | 2026-11-16 | 10-Q
Sources - News headlines
  • N1 | 2026-11-16 | www.nasdaq.com | Vivos Therapeutics, Inc. (VVOS) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/vivos-therapeutics-inc-vvos-reports-q3-loss-beats-revenue-estimates
  • N2 | 2026-11-16 | www.nasdaq.com | Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates | https://www.nasdaq.com/articles/prelude-therapeutics-incorporated-prld-reports-q3-loss-beats-revenue-estimates
  • N3 | 2026-11-12 | www.nasdaq.com | Journey Medical Corporation (DERM) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/journey-medical-corporation-derm-reports-q3-loss-lags-revenue-estimates
  • N4 | 2026-11-09 | www.nasdaq.com | Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/heron-therapeutics-hrtx-reports-q3-loss-misses-revenue-estimates
  • N5 | 2026-11-05 | www.nasdaq.com | ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates | https://www.nasdaq.com/articles/ars-pharmaceuticals-inc-spry-reports-q3-loss-lags-revenue-estimates
  • N6 | 2026-10-21 | www.nasdaq.com | Vivos Therapeutics, Inc. Regains Compliance with Nasdaq Stockholders' Equity Standard | https://www.nasdaq.com/articles/vivos-therapeutics-inc-regains-compliance-nasdaq-stockholders-equity-standard
  • N7 | 2026-08-28 | www.nasdaq.com | Vivos Therapeutics Advances South Florida Sleep Center With South Palm Cardiovascular Partnership | https://www.nasdaq.com/articles/vivos-therapeutics-advances-south-florida-sleep-center-south-palm-cardiovascular
  • N8 | 2026-08-20 | www.nasdaq.com | Vivos Therapeutics Boosts Nevada Capacity With New $10M Revenue-Target Facility | https://www.nasdaq.com/articles/vivos-therapeutics-boosts-nevada-capacity-new-10m-revenue-target-facility
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine